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Triggering of B7h by the ICOS Modulates Maturation and
Migration of Monocyte-Derived Dendritic Cells
Sergio Occhipinti,*,1 Chiara Dianzani,†,1 Annalisa Chiocchetti,‡,1 Elena Boggio,‡
Nausicaa Clemente,‡ Casimiro Luca Gigliotti,‡ Maria Felicia Soluri,‡ Rosalba Minelli,†,‡
Roberto Fantozzi,† Jungi Yagi,x Jose` Maria Rojo,{ Daniele Sblattero,‡ Mirella Giovarelli,*
and Umberto Dianzani‡
B7h, expressed by several cell types, binds ICOS expressed by activated T cells. We have previously shown that B7h triggering by
ICOS-Fc inhibits human endothelial cell adhesiveness. This work investigated the effect of ICOS-Fc on human monocyte-derived
dendritic cells (DCs). We found that DCs matured with LPS in the presence of ICOS-Fc (mDCsICOS) produced greater amounts of
IL-23 and IL-10, and promoted a higher secretion of IL-17A and IL-17F in MLCs than did those DCs matured with LPS alone
(mDCs). Moreover, mDCsICOS pulsed with the keyhole limpet hemocyanin Ag during the maturation phase were better stim-
ulators of Ag-specific MHC class I–, but not class II–restricted T cells than mDCs. This was probably due to promotion of cross-
presentation because it was not detected when the Flu-MA58–66 Ag was directly loaded on already matured DCs and mDCs
ICOS.
Finally, ICOS-Fc inhibited the adhesion of both immature DCs and mDCs to vascular and lymphoid endothelial cells, their mi-
gratory activity, and the expression of the Rac-1 activator b-Pix involved in cell motility. These data suggest that B7h stimulation
modulates DC function with effects on their maturation and recruitment into tissues. This opens a novel view on the use of
interactors of the ICOS:B7h system as immunomodulatory drugs. The Journal of Immunology, 2013, 190: 1125–1134.
F
ull activation of naive T cells requires their receipt of three
signals from APC (1). The first is delivered through the
TCR upon recognition of the antigenic peptide presented
by the appropriate MHC, the second is provided by T cell costimu-
latory molecules engaged by their ligands expressed on APC, and
the third is delivered by cytokines in the microenvironment. In the
absence of these signals, T cells become anergic or die by apoptosis
(2). CD28, the best known T cell costimulatory molecule, is con-
stitutively expressed by T cells. It binds B7.1 (CD80) and B7.2
(CD86) on APC, and promotes T cell proliferation and cytokine
secretion (3, 4). CTLA-4 belongs to the CD28 family and binds the
same ligands as CD28, but it transduces negative signals, down-
modulating T cell activation. B7.1 and B7.2 also transduce signals
upon engagement by CD28 or CTLA-4 and modulate APC func-
tion: this has been described as “reverse signaling” (5). Reverse
signaling triggered by CD28-Fc, a fusion molecule of the extra-
cellular portion of CD28 with the Fc portion of IgG, leads to the
production of IL-6 from mouse dendritic cells (DCs), and thus re-
sults in their activation, whereas CTLA-4–Fc upregulates IDO and
degrades tryptophan to products that inhibit T cell proliferation (5,
6). Other members of the CD28 family are ICOS, programmed
death 1, and B and T lymphocyte attenuator (7–10), whereas other
members of the B7 family are B7h, B7H1, B7H3, B7H4, and B7-
DCs (10–14).
ICOS (CD278) is a costimulatory molecule selectively expressed
by activated T cells (7, 15–17). It binds B7h (CD275, also known
as B7H2, B7-RP1, ICOSL, GL50) expressed by both hematopoi-
etic and nonhematopoietic cells. B7h is constitutively expressed
by B cells, macrophages, DCs, and a subset of mouse spleen T cells.
In monocytes, expression is upregulated upon activation. B7h is
also expressed by vascular endothelial cells (ECs), epithelial cells,
and fibroblasts (3, 18–24). This expression pattern suggests that
the ICOS–B7h interaction has a role in both T cell activation in
lymphoid organs and the control of T cell function at sites of in-
flammation. ICOS function has been extensively investigated in
T cells, where it seems to modulate cytokine secretion by pre-
dominantly acting on recently activated/memory cells, whereas
it is less effective in naive T cells, whose activation and IL-2 secre-
tion seem to mainly depend on CD28 costimulation (3, 7, 10, 25–
27). Moreover, substantial differences in ICOS function have been
reported in mouse and human cells. In mice, ICOS triggering has
been predominantly related to induction of IL-4–secreting Th2
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cells or IL-10–secreting regulatory T cells, but it can also induce
IFN-g–secreting Th1 cells and support IL-17–secreting Th17 cells
in some circumstances (28–30). In humans, it has been reported that
ICOS-mediated costimulation of naive Th cells elicits different
responses depending on the cytokine milieu, because it promotes
IFN-g secretion in the presence and IL-10 and TGF-b secretion in
the absence of IL-2 (31). Moreover, ICOS triggering has been
shown to induce IL-17 secretion in a subset of cord blood cells
(32). The differences between the two species might be partly
because of the B7h capacity to weakly interact with CD28 and
CTLA-4 in humans but not in mice, using binding sites different
from that interacting with ICOS (33).
The primary aim of this work was to assess a different aspect
of ICOS function, that is, the reverse signaling, triggered through
B7h, on human DCs, and it was prompted by our recent research
showing that B7h ligation by ICOS-Fc significantly inhibits the
capacity of HUVECs to adhere to several tumor cell lines and poly-
morphonuclear cells. Therefore, the B7h–ICOS interaction may
modulate the spread of cancer metastases and the recruitment of
polymorphonuclear cells in inflammatory sites (34). Moreover,
other authors have shown that, in mice, B7h triggering induces
partial maturation of immature DCs (iDCs) with prominent aug-
mentation of IL-6 secretion (35).
In peripheral tissues, iDCs are specialized in Ag uptake and
processing for MHC presentation (36, 37). In the presence of in-
flammatory mediators, such as TLR ligands and inflammatory cy-
tokines, iDCs differentiate to DCs matured with LPS alone (mDCs)
able to activate T cells and characterized by decreased endocytic
activity, increased expression of costimulatory and MHC class II
(MHC-II) molecules, and increased cytokine secretion (38–40).
They are at least 100 times more potent than macrophages in ac-
tivating naive T cells in vitro and are able to “cross-present” endo-
cytosed proteins on MHC class I (MHC-I), in addition to the
standard presentation on MHC-II (41, 42). iDCs are recruited to
sites of inflammation by inducible inflammatory chemokines, such
as CCL5, whereas mDCs are directed to draining secondary lym-
phoid tissues by constitutive chemokines, such as CCL19 and
CCL21, via upregulation CCR7 (43). In this study, we show that
the triggering of B7h substantially modulates LPS-induced matu-
ration of DCs by influencing cytokine secretion and promoting
cross-presentation. Moreover, it inhibits DC adhesiveness to ECs,
their migratory activity, and expression of the Rac-1 activator b-Pix
involved in cell motility.
Materials and Methods
Cells
PBMCs were obtained by density gradient centrifugation from buffy coats
provided by the local Blood Transfusion Service (Novara, Italy). iDCs were
prepared from CD14+ monocytes, isolated from PBMCs with the Mono-
cyte Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany), by
culture for 5 d in culture medium, composed of RPMI 1640 (Invitrogen,
Burlington, ON, Canada), 2 mM L-glutamine (Invitrogen), and 10% FBS
(Invitrogen) or serum-free medium supplement (Lonza, Basel, Switzerland),
supplemented with recombinant human GM-CSF (800 U/ml; Immuno-
tools, Friesoythe, Germany) and IL-4 (10 ng/ml; R&D Systems, Minne-
apolis, MN). Cytofluorimetric characterization showed that monocytes
expressed CD14 and B7.2, but not CD1a, B7.1, and B7h. In iDCs, CD1a,
B7.1, and B7h were upmodulated, CD14 was downmodulated, and B7.2
was unchanged (data not shown).
In the maturation assays, iDCs were cultured for 2 additional days in
culture medium in the presence of 1 mg/ml LPS (Escherichia coli, serotype
055:B5; Sigma-Aldrich, St. Louis, MO) or 1 mg/ml ICOS-Fc, or both.
ICOS-Fc was a fusion protein of the extracellular portion of human ICOS
fused to the human IgG1 Fc, and similar results were obtained with pur-
chased (R&D Systems) and in-house produced reagents (34). Controls
were performed using in-house produced F119SICOS-Fc, carrying the
F119S substitution in the ICOS amino acid sequence, ICOS-mouse Fc
(ICOS-msFc), in which the human ICOS was fused with a mouse Fcg
portion, and 1 mg/ml CTLA-4–Fc (R&D Systems). In some experiments,
the soluble human IgG1 Fc was also used as a control (R&D Systems) and
had no effect on DC maturation (data not shown).
The DC surface phenotype was assessed by immunofluorescence and
flow cytometry using FITC- and PE-conjugated (mAb) to CD14, HLA-DR
(Caltag, Burlingame, CA), CD1a, CD80, CD83, CD86, HLA-A, -B, -C
(Becton Dickinson Pharmingen, San Jose, CA), and B7h (BioLegend, San
Diego, CA).
Mannose receptor–mediated endocytosis
Cell endocytosis was assessed by evaluating uptake of FITC-dextran
(molecular mass 70 kDa; Invitrogen). In brief, each DC sample was
split into two fractions of 1 3 105 cells that were incubated with 1 mg/
ml FITC-dextran at either 37˚C or 0˚C for 60 min. Uptake was then
stopped by adding ice-cold PBS followed by extensive washes in a re-
frigerated centrifuge, and cells were analyzed by flow cytometry. Ag
uptake was expressed as the difference of mean fluorescence intensity
between the test sample performed at 37˚C and the control sample
performed at 4˚C.
Mixed lymphocyte cultures
DCs (5 3 103) were cocultured in 96-well round-bottom plates for 5 d at
a 1:20 DC/lymphocyte ratio with allogeneic PBLs or CD8+ or CD4+
T cells purified with the Human CD8 or CD4 Microbeads kits (Miltenyi
Biotec). Supernatants were then collected and used for cytokine analysis.
In the final 6 h of culture, 0.5 mCi [3H]thymidine (Perkin Elmer, Waltham,
MA) was added to each well; cells were then harvested with a semiauto-
matic cell harvester and their radioactivity was measured with a beta counter
(Perkin Elmer).
Cytokine analysis
IL-1b, IL-2, IL-4, IL-6, IL-10, IL-12p70, IL-17A, IL-17F, IL-21, IL-22,
IL-23, CCL20, TNF-a, and IFN-g were evaluated using standard ELISA
(R&D Systems; BioLegend).
Ag presentation assays
iDCs were resuspended at 1 3 106/ml in serum-free RPMI 1640 and in-
cubated with 10 mg/ml keyhole limpet hemocyanin (KLH; Calbiochem,
Darmstadt, Germany) for 6 h at 37˚C. They were then washed and
resuspended in RPMI 1640 supplemented with 5% heat-inactivated AB
human serum (Lonza), and matured for 24 h with LPS in presence or not of
ICOS-Fc. They were then cocultured with autologous T cells, purified with
the Human PanT Microbeads Kit (Milteniy Biotec) at a DC/T ratio of 1:10.
On day 7, specific activation was evaluated by ELISPOT assay on total
T cells or on CD8+ or CD4+ T cells purified with the Human CD8 or CD4
Microbeads kits (Miltenyi Biotec).
Differentially mDCs from HLA-A2+ donors were resuspended at 1 3
106/ml in serum-free RPMI 1640, pulsed with the influenza matrix Flu-
MA58–66 peptide (3 mg/ml; GILGFVFTL; Primm) for 4 h at 37˚C, and then
cultured with autologous T cells at a 1:10 ratio, to assess whether ICOS-Fc
modulated the ability to present HLA-A2–restricted peptides to T cells. On
day 7, the recovered cells were restimulated in the same conditions by Flu-
MA58–66–pulsed DCs and 1 ng/ml rIL-2 (Sigma-Aldrich). After another
7 d, specific activation was evaluated by ELISPOT assay.
HLA-A2+ CD8+ T clones specific for Flu-MA58–66 provided by Dr.
Claudia Giachino (University of Torino, Torino, Italy) were expanded in
RPMI 1640 supplemented with 5% AB human serum and IL-2 (250 U/ml;
Sigma-Aldrich), and expanded every 2 wk with 1 mg/ml PHA (Sigma-
Aldrich), 250 U/ml IL-2, and 0.5 3 106/ml allogenic-irradiated PBMCs.
They were used for the functional test 2 wk after stimulation.
ELISPOT assay
A total of 5 3 104 T cells were cultured, at a 30:1 ratio, with unpulsed or
KLH-pulsed mDCs in a final volume of 100 ml AIM-V medium (Invi-
trogen) in 96-well ELISPOT assay plates (Millipore, Bedford, MA), pre-
viously coated with 100 ml human primary anti–IFN-g mAb solution (BD
Biosciences). In some experiments, 5 3 103 Flu-MA58–66 T cells were
cultured, at a 10:1 ratio, with unloaded and Flu-MA58–66–loaded mDCs.
ELISPOT assays were performed following the manufacturer’s instruc-
tions. Substrate (AEC Staining Kit; Sigma-Aldrich) was added to each
well to develop the spots. Reaction was stopped after 10–20 min with
water, and the membrane was left to dry in the dark. The spots were
counted by computer-assisted image analysis (Transtec 1300 ELISpot
Reader; AMI Bioline, Buttigliera Alta, Italy). Data are expressed as
number of specific spots/105 cells; specific spots were those obtained in
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the presence of Ag-pulsed DCs minus those obtained in the presence of
Ag-unpulsed DCs.
Cells adhesion assay
HUVECs were isolated from human umbilical veins by trypsin treatment
(1%) and cultured in M199 medium (Lonza) with the addition of 20% FCS
and 100 U/ml penicillin, 100 mg/ml streptomycin, 5 UI/ml heparin, 12 mg/ml
bovine brain extract, and 200 mM glutamine. HUVECs were grown to
confluence in flasks and used at the second to fifth passage. Informed
consent was obtained from all donors. Human dermal lymphatic ECs
(HDLECs) were purchased from PromoCell and cultured with Endothelial
Cell Growth Medium MV2 (PromoCell, Heidelberg, Germany).
HUVECs and HDLECs were grown to confluence in 24-well plates and
then treated or not with ICOS-Fc, or F119SICOS-Fc or CTLA-4–Fc (2 mg/
ml) for 30 min, washed with fresh medium twice, and incubated for 1 h
with the iDCs or mDCs (5 3 104 cell/well). The 1-h incubation time was
chosen to allow full sedimentation of the adhering cells, but similar results
were obtained with a shorter incubation time (30 min). In some experi-
ments, iDCs or mDCs and HUVECs or HDLECs were pretreated with
ICOS-Fc, or F119SICOS-Fc, or CTLA-4–Fc (2 mg/ml) for 30 min, washed
with fresh medium twice, and used in the adhesion assays. After incubation
in the adhesion assay, nonadherent cells were removed by washing three
times with M199. The center of each well was analyzed by fluorescence
image analysis (33). Adherent cells were counted by the Image Pro Plus
Software for microimaging (version 5.0; Media Cybernetics, Bethesda,
MD). Single experimental points were assayed in triplicate, and the SE of
the three replicates was always ,10%. Data are shown as percentages of
inhibition versus the control adhesion measured on untreated HUVECs or
HDLECs; this control adhesion was 25 6 2 cells/microscope fields (n = 6)
for iDCs and in a similar range for mDCs, in the adhesion to both
HUVECs and HDLECs.
Migration assay
To determine the effects of ICOS-Fc on iDCs or mDCs migration, we used
the Boyden chamber (BDBiosciences) migration assay. iDCs or mDCs (53
103 cells/well) were plated onto the apical side of 50 mg/ml Matrigel-
coated filters in serum-free medium in the presence and absence of ICOS-
Fc, or F119SICOS-Fc, or CTLA-4–Fc (2 mg/ml). Medium containing 1026 M
N-formyl-Met-Leu-Phe (nfMLP; Sigma-Aldrich) or 200 ng/ml CCL5 (R&D
Systems) was placed in the basolateral chamber as chemoattractant for
iDCs; 250 ng/ml CCL19 (R&D Systems) or 250 ng/ml CCL21 (R&D
Systems) was used as chemoattractant for mDCs. After 6 h, the cells on
FIGURE 1. Cytokine secretion of DCs treated with
different stimuli. B7h triggering substantially modu-
lates the cytokine pattern secreted by DCs. DCs were
cultured with LPS in the presence and absence of either
ICOS-Fc, ICOS-msFc, F119SICOS-Fc, or CTLA-4–Fc
in serum-free medium, and culture supernatants were
harvested after 2 d and examined for cytokine pro-
duction by ELISA. Data represent the median and IQR
of results from eight independent experiments per-
formed in triplicate and marked with distinct symbols.
*p , 0.05 versus mDCs.
The Journal of Immunology 1127









the apical side were wiped off with cotton swabs. Cells on the bottom of
the filter were stained with crystal violet and counted (five fields of each
triplicate filter) with an inverted microscope. The results are expressed as
the number of migrated cells per high-power field.
Western blot analysis
Cells were treated or not with ICOS-Fc or F119SICOS-Fc (4 mg/ml) at 37˚C
for 30 min. Then they were lysed in 20 mM Tris-HCl, pH 7.4, 150 mM
NaCl, 5 mM EDTA, 1% v/v Triton X-100, phosphatase and protease
(P2850, P8340; Sigma-Aldrich) inhibitors for 20 min at 4˚C. The super-
natants were collected after centrifugation at 14,000 rpm for 30 min, and
35 mg proteins was run in a 9.3% SDS-PAGE and transferred onto a ni-
trocellulose membrane. Filters were blocked with TBS (10 mM Tris HCl
pH 7.9; 150 mM NaCl) containing 5% nonfat milk and 1% Tween 20 for
1 h at room temperature, and probed overnight with anti–b-Pix (SH3
domain) rabbit polyclonal Ab (Millipore, Billerica, MA) followed by the
appropriate HRP-conjugated secondary reagent and detected by ECL.
Densitometric analysis was performed by the Multi-Analyst (version 1.1;
Bio-Rad Laboratories, Hercules, CA).
Statistical analysis
Statistical analysis was performed using the Friedman test followed by
a Dunn post hoc analysis. Results are shown as medians and interquartile
ranges (IQRs).
Results
Effect of B7h stimulation on DC maturation
Monocytes were induced to differentiate to iDCs by a 5-d culture
with GM-CSF and IL-4. Because activation stimuli, such as LPS,
induce iDCs maturation to mDCs, we assessed the effect of B7h
stimulation in this process by using ICOS-Fc to trigger B7h. iDCs
were treated for 2 d with control medium (iDCs), LPS (mDCs),
immature DCs treated with ICOS-Fc (iDCsICOS), or LPS plus
ICOS-Fc (mDCsICOS). We then compared their surface marker
expression and endocytic, cytokine secretion, allostimulatory, and
Ag presentation activities.
Analysis of surface expression of B7h, B7.1, B7.2, CD83, HLA-
DR, and class I HLA showed that treatment with LPS upregulated
B7.1, B7.2, CD83, HLA-DR, and class I HLA as expected, whereas
ICOS-Fc had no effect because no differences were found com-
paring iDCs with iDCsICOS and mDCs with mDCsICOS (data not
shown). Endocytic activity was assessed by evaluating uptake
of FITC-conjugated dextran. Results showed that ICOS-Fc did not
exert any effect on this activity because iDCs and iDCsICOS dis-
played the same ability to capture Ags, and that this activity was
similarly downregulated in mDCs and mDCsICOS (data not shown).
Assessment of cytokine secretion by measuring levels of IL-1b,
IL-6, IL-10, IL-12p70, IL-23, and TNF-a in the supernatants of
the 2-d DCs cultures showed that secretion of all these cytokines
was almost undetectable in iDCs and it was unchanged in iDC-
sICOS (data not shown). Treatment with LPS upregulated secretion
of IL-6, IL-10, IL-12p70, IL-23, IL-1b, and TNF-a, and intrigu-
ingly, mDCsICOS displayed a different cytokine secretion pattern
from mDCs, with higher secretion of IL-23 and IL-10, and lower
secretion of IL-6 and, to a lesser extent, TNF-a (Fig. 1). By
contrast, secretion of IL-12p70 and IL-1b were unchanged (Fig.
1). To assess the specificity of the ICOS-Fc effect, we induced
mDC maturation in the presence of either F119SICOS-Fc, which is
a mutated form of ICOS incapable to bind B7h (44), or ICOS-
msFc, in which the human ICOS was fused with a mouse Fcg
portion to minimize interaction with the human Fcg receptors, or
CTLA-4–Fc, which binds B7.1/B7.2, but not B7h. Results showed
that ICOS-msFc exerted the same effect as ICOS-Fc, whereas F119S
ICOS-Fc did not exert any effect. CTLA-4–Fc increased IL-10,
decreased IL-6, and did not change IL-12p70 and IL-1b similarly
to ICOS-Fc, but differently from ICOS-Fc, it had no effect on IL-
23 and TNF-a (Fig. 1).
Evaluation of the DCs allostimulatory activity, by assessing
the lymphocyte proliferative response of PBLs, CD4+ T cells, and
CD8+ T cells in allogeneic MLCs, showed that lymphocyte pro-
liferation induced by mDCs was significantly higher than that
induced by mDCsICOS in all lymphocyte preparations (Fig. 2). To
assess whether differences in cytokine secretion displayed by
mDCs and mDCsICOS paralleled differences in their ability to
polarize the Th cell response, we evaluated secretion of IFN-g, IL-
2, IL-4, IL-10, IL-17A, IL-17F, IL-21, IL-22, and CCL20 in the
supernatants from these MLCs. Compared with mDC-driven
MLCs, MLCs driven by mDCsICOS displayed significant upmod-
ulation of IL-17A and IL-17F, and downmodulation of IL-2 in
PBLs and CD4+ T cells (Fig. 3). The effects induced by ICOS-Fc
were not ascribable to binding of the Fcg1 portion of ICOS-Fc to
DCs FcgRs, because they were also displayed by mDCs matured
in the presence of ICOS-msFc, but not by those matured in the
presence of F119SICOS-Fc (Fig. 3). By contrast, mDCs and mDCsICOS
did not differ in their capacity to induce secretion of IFN-g, IL-10,
and CCL20 in all lymphocyte populations and IL-2 in CD8+
T cells (Supplementary Table I). IL-4, IL-21, and IL-22 were un-
detectable in every cell population and in all experimental con-
ditions (data not shown).
Similar experiments performed using iDCs and iDCsICOS de-
tected minimal MLC proliferation and cytokine secretion with
no substantial differences between iDCs and iDCsICOS (data not
shown).
In the MLCs, the ICOS-Fc effects were not due to decreased
interaction between ICOS on T cells and B7h on DCs as a con-
sequence of B7h downmodulation or blocking by the ICOS-Fc used
to prepare mDCsICOS. Staining with anti-B7h mAb showed, in
fact, similar expression levels in mDCs and mDCsICOS, and staining
of these cells with anti-human Ig Abs did not disclose any residual
ICOS-Fc bound on the cell surface (data not shown). Moreover,
surface expression of ICOS was not different in T cells activated in
the different MLC settings (data not shown).
Effect of B7h stimulation on Ag presentation
iDCs were pulsed with KLH, matured with LPS in the presence and
absence of ICOS-Fc, and then used as stimulators of autologous
T cells, to assess whether B7h triggering modulates DCs Ag
FIGURE 2. Alloreactive proliferation induced in different lymphocyte
populations by DCs treated with different stimuli. mDCs were prepared in
the presence and absence of either ICOS-Fc, ICOS-msFc, or F119SICOS-
Fc, and used as stimulators against allogeneic PBLs or purified CD4+ or
CD8+ cells at a stimulator/responder ratio of 1:20 for 5 d. [3H]thymidine
(0.5 mCi/well) was added in the final 6 h of culture, and radioactivity
uptake was measured by a beta counter; data are expressed as median and
IQR of the results from six experiments performed in triplicate and marked
with distinct symbols. *p , 0.05 versus mDCs.
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presentation (45). After 7 d of primary culture, T cells were rechal-
lenged with the same stimulators in the presence and absence of
MHC-I or MHC-II blocking Abs; secretion of IFN-g was then as-
sessed by ELISPOT to detect the MHC-II– and MHC-I–restricted
response, respectively, because IFN-g secretion can efficiently
detect activation of both CD4+ and CD8+ T cells. The results
showed that mDCsICOS induced higher proportions of IFN-g–
secreting, MHC-I–restricted cells than mDCs, whereas both stim-
ulators elicited similar responses in the MHC-II–restricted population
(Fig. 4A). Moreover, mDCsICOS displayed a similar stimulatory
activity when matured in the presence of either ICOS-Fc or ICOS-
msFc, whereas those matured in the presence of F119SICOS-Fc
displayed a similar activity as plain mDCs. By contrast, mDCs ma-
tured in the presence of CTLA-4–Fc displayed lower stimulatory
activity than plain mDCs in both MHC-I– and MHC-II–restricted
T cells (Fig. 4A), which is in line with the notion that CTLA-4–Fc
induces suppressive functions in DCs (6). To confirm these results,
in a distinct set of experiments, we purified CD4+ and CD8+ cells
from the 7-d primary culture, rechallenged them with the same
stimulators, and analyzed them for IFN-g secretion by ELISPOT.
The results obtained with the different ICOS-Fc variants on pu-
rified CD4+ and CD8+ cells strictly paralleled those obtained with
whole T cells in the presence of anti–MHC-I and –MHC-II Abs,
respectively. The inhibitory effect of CTLA-4–Fc also was still de-
tectable, but it was significant in CD4+ cells only (Fig. 4B). Similar
experiments performed in iDCs showed that iDCs and iDCsICOS
displayed a similar low capacity to induce IFN-g–secreting
cells in both MHC-I– and MHC-II–restricted T cells (data not
shown).
The increased ability of mDCsICOS to activate MHC-I–restricted
T cells might be ascribed to potentiation of their capacity to cross-
present endocytosed Ags in MHC-I or to increase of their intrinsic
costimulatory activity. To distinguish between these possibilities,
mDCs and mDCsICOS obtained from HLA-A2+ donors were
FIGURE 3. Cytokine secretion induced in different
lymphocyte population by DCs treated with different
stimuli. mDCs were prepared in the presence and ab-
sence of either ICOS-Fc, ICOS-msFc, or F119SICOS-
Fc, and used as stimulators as described in Fig. 2.
Cytokine secretion was assessed in the supernatants by
ELISA after 5 d of culture; data are expressed as me-
dian and IQR of results from six experiments per-
formed in triplicate and marked with distinct symbols.
*p , 0.05 versus mDCs.
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pulsed with the influenza virus matrix peptide Flu-MA58–66 after
their maturation in order directly to load the peptide on surface
HLA-A2 molecules, skipping the Ag processing step, and then
used to activate autologous T cells. ELISPOT analysis of IFN-g–
secreting cells showed similar proportions of positive cells using
mDCs, mDCsICOS, or those matured in the presence of either
ICOS-msFc or F119SICOS-Fc, or CTLA-4–Fc (Fig. 4C). To con-
firm these results, we repeated the experiments using CD8+ T cell
clones specific for Flu-MA58–66 presented on HLA-A2
+, as re-
sponder cells. Also in this case, ELISPOT analysis did not detect
substantial differences using the different stimulators (Fig. 4C).
These data indicated that the increase of mDCsICOS ability to
activate MHC-I–restricted T cells might be ascribed to promotion
of Ag cross-presentation and not to an increase in their costimu-
latory activity toward CD8+ T cells.
Effect of B7h stimulation on DC adhesiveness and migration
In a previous work, we showed that ICOS-Fc inhibited adhesion of
several tumor cell lines to HUVECs by triggering B7h expressed
on either HUVECs or the tumor cell lines. To assess the effect of
B7h triggering on iDC and mDC adhesion to ECs, we performed
adhesion assays using both HUVECs and HDLECs. Either DCs or
the EC lines were pretreated or not with ICOS-Fc for 30 min,
washed, and incubated together in the adhesion assay; as a control,
cells were treated with F119SICOS-Fc or CTLA-4–Fc. The results
showed that pretreatment with ICOS-Fc significantly inhibited
adhesion of both iDCs and mDCs to both HUVECs and HDLECs
by ∼50%. Inhibition was similar when B7h was triggered on ei-
ther ECs or DCs, or both cell types. By contrast, pretreatment with
F119SICOS-Fc or CTLA-4–Fc had no effect (Fig. 5).
Because adhesive mechanisms are also involved in DC migra-
tion, we used a Boyden chamber migration assay to investigate the
effect of B7h triggering on spontaneous migration of iDCs and
mDCs, migration of iDCs driven by nfMLP or CCL5, and mi-
gration of mDCs driven by CCL19 or CCL21. iDCs or mDCs were
seeded in the upper chamber of a Boyden chamber in the absence
and presence of either ICOS-Fc, F119SICOS-Fc, or CTLA-4–Fc,
and left to migrate toward the lower chamber loaded with medium
FIGURE 4. Ag presentation activity of iDCs in-
duced to mature with several stimuli. iDCs pulsed with
KLH and matured with LPS in the presence and ab-
sence of ICOS-Fc, ICOS-msFc, F119SICOS-Fc, or
CTLA-4–Fc were used as stimulators of autologous
T cells in 7-d cultures. (A) Lymphocytes recovered
from each culture were restimulated in IFN-g ELI-
SPOT plates with the same stimuli in the presence and
absence of MHC-I (left panel) or MHC-II (right panel)
blocking Abs (n = 6). (B) CD4+ and CD8+ cells were
purified from the lymphocytes recovered from each
culture and then restimulated in IFN-g ELISPOT plates
with the same stimuli (n = 6). (C) HLA-A2+ DCs
matured with LPS in the absence and presence of
ICOS-Fc, ICOS-mFc, F119SICOS-Fc, or CTLA-4–Fc,
and subsequently loaded with Flu-MA58–66 were used
to stimulate autologous T cells previously expanded
with the same stimulus (left panel) or HLA-A2+–
matched anti–Flu-MA58–66 CD8
+ T cell clones (right
panel) in IFN-g ELISPOT plates (n = 4). Data are
expressed as number of specific spots and are the me-
dians and IQR of the results from four to six experi-
ments performed in triplicate and marked with distinct
symbols. *p , 0.05 versus mDCs.
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in the absence or presence of the earlier indicated chemotactic
agents. The results showed that iDCs and mDCs displayed a spon-
taneous migration that was increased by each chemoattractant
and, in all conditions, substantially inhibited by ICOS-Fc, but not
by F119SICOS-Fc and CTLA-4–Fc (Fig. 6).
ICOS-Fc alters b-Pix–mediated signaling
b-Pix is an Rac-1 activator involved in cell migration (46). Its
downmodulation inhibits cell spreading, lamellipodial formation,
and integrin-induced increase of Rac1 activity. To evaluate whether
treatment with ICOS-Fc influences b-Pix expression, we treated
iDCs and mDCs with ICOS-Fc or F119SICOS-Fc for 30 min and
then analyzed b-Pix expression by Western blot. Results showed
that treatment with ICOS-Fc decreased expression of b-Pix in both
iDCs and mDCs, whereas no effect was exerted by F119SICOS-Fc
(Fig. 7).
Discussion
This work showed that reverse signaling mediated by B7h mod-
ulated the DC response to LPS by influencing cytokine secretion
and the ability to drive T cell activation and differentiation. More-
over, it modulated DC adhesiveness and migration.
Analysis of surface marker expression, endocytic activity, and
cytokine secretion showed that B7h triggering per se was unable to
induce DC maturation, whereas, as expected, this was induced by
LPS with downregulation of endocytic activity and upregulation of
B7.1, B7.2, CD83, and MHC expression, allostimulatory activity,
and secretion of TNF-a, IL-6, IL-12, IL-10, and IL-23. Treatment
with either ICOS-Fc or CTLA-4–Fc modulated this LPS-induced
cytokine secretion with increase of IL-10 and decrease of TNF-a
and IL-6, whereas IL-23 secretion was increased by ICOS-Fc
only.
IL-1b and IL-6 are involved in differentiation of proinflammatory
Th17 cells characterized by secretion of IL-17, IL-21, IL-22, and
IL-26, whereas IL-23 is involved in their expansion (30, 47, 48).
Therefore, B7h triggering in DCs may promote expansion of
differentiated Th17 cells through the increased IL-23 secretion,
which was supported by the finding that mDCsICOS stimulated
higher secretion of IL-17A and IL-17F than did plain mDCs in
MLC assays. By contrast, they did not influence secretion of IL-21
and IL-22, secreted by subsets of Th17 cells (49, 50). Therefore,
B7h triggering seemed to modulate DCs maturation by increasing
their ability to expand Th17 cells, which was intriguing in light of
data showing that the triggering of ICOS on T cells supports
differentiation of Th17 cells in the presence of appropriate cyto-
kine milieus (32). Therefore, the ICOS–B7h interaction between
DCs and T cells may trigger bidirectional signals that biphasically
cooperate to induce and expand Th17 cells. In the T cell activation
step, ICOS triggering promotes differentiation of Th17 cells; in
the DC maturation step, B7h triggering promotes secretion of IL-
23, supporting Th17 cell expansion.
A further effect mediated by B7h triggering was potentiation of
mDCs ability to activate the T cell response to endocytosed Ags in
the context of MHC-I involving CD8+ T cells, but not in the
context of MHC-II involving CD4+ T cells. This seemed to be due
to increased cross-presentation of the Ag and not to increased
expression of either MHC-I or costimulatory molecules involved
in activation of CD8+ T cells. The effect of B7h triggering, in fact,
required Ag processing because it was detectable when KLH was
loaded on maturing DCs, but not when the Flu-MA58–66 peptide
was loaded on already matured DCs. Specificity was shown by the
ineffectiveness of F119SICOS-Fc and by the different effect exerted
by CTLA-4–Fc, which inhibited mDCs ability to activate both the
MHC-I– and MHC-II–restricted responses to KLH; this is in line
with reports showing that CTLA-4–Fc induces DCs to produce
the suppressive molecule IDO (6). Incomplete understanding of
the molecular machinery of cross-presentation makes difficult to
conjecture how it may be supported by B7h triggering. However,
FIGURE 5. Effect of ICOS-Fc on iDC and mDC ad-
hesion to EC lines. EC lines (HUVECs and HDLECs)
and/or DCs (iDCs and mDCs) were pretreated or not
with ICOS-Fc, F119SICOS-Fc, or CTLA-4–Fc (2 mg/ml)
for 30 min, washed, and then incubated together for 1 h
in the adhesion assay. The legend of the horizontal axes
shows which cells were pretreated with the indicated
reagent. Data are expressed as the percentage of inhi-
bition versus the control adhesion obtained with un-
treated cells, and are the medians and IQR of the results
from five experiments performed in triplicate. *p ,
0.05 versus the control.
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it is noteworthy that the Th17-switch induced by B7h-stimulated
DCs might further support the cross-presentation induced by B7h
stimulation because IL-17 has been shown to promote cross-pre-
sentation in mice (51).
These results are quite different from those reported in regard to
mouse bone marrow–derived DCs by Tang et al. (35) showing that,
in the absence of other stimuli, B7h triggering induced partial mat-
uration of iDCs. This is mediated by a p38 MAPK-dependent
signal with selective augmentation of IL-6 secretion; a similar
effect was detected by Orabona et al. (5) by using CD28-Fc to
trigger B7.1 and B7.2. Moreover, in these murine DCs, B7h trig-
gering increased expression of CD80, CD83, CD86, and MHC-II,
phagocytosis, and Ag presentation to CD4+ Th cells, and sup-
ported their polarization to Th1 cells (35). However, the differ-
ences between these data on mice and our results on human DCs
are not surprising in light of the several different functions that
ICOS displays in the two species (25–31). Finally, B7h trig-
gering substantially inhibited adhesion of both iDCs and mDCs
to vascular and lymphoid ECs, and their spontaneous and che-
mokine-driven migration. Again, the effect was specific because it
was not induced by F119SICOS-Fc and CTLA-4–Fc. Apparently,
the effect was not due to modulation of the expression of adhesion
molecules or chemokine receptors, as detected by surface immu-
nofluorescence of CCR1, CCR7, ICAM-1, ICAM-2, VCAM-1,
mucosal addressin cell adhesion molecule, E-selectin (CD62E),
CD62P, CD15s (Sialyl Lewis X), Sialyl Lewis A, CD31, CD34,
CD40, and CD44v (data not shown).
By contrast, ICOS-Fc downregulated expression of b-Pix, a
Rac-1 activator recruited by activated integrins and required for
rapid nascent adhesion turnover. Downregulation of b-Pix expres-
sion prevents cell spreading, lamellipodial formation, and increase
of Rac1 activity (44, 52, 53). By contrast, in DCs, we did not detect
any effect in ERK phosphorylation that we have previously shown
to be downmodulated by ICOS-Fc in ECs (34), and similar nega-
tive results were obtained on JNK, p38, AKT, STAT1, and STAT3
(data not shown).
DCs are the most potent APC of the immune system involved in
the initiation of the acquired immune response, and they are the
FIGURE 6. Effect of ICOS-Fc on iDC and mDC
migration. iDCs or mDCs were plated into the apical
side of Matrigel-coated filters in the presence and
absence of ICOS-Fc, F119SICOS-Fc, or CTLA-4 (2 mg/
ml). The basolateral chamber was loaded with me-
dium in the presence and absence of nfMLP or CCL5
for iDCs, and CCL19 or CCL21 for mDCs. The cells
migrated to the bottom of the filters were stained using
crystal violet and counted (five fields of each triplicate
filters) using an inverted microscope after 6 h. Data
are expressed as the migrated cells in each condition,
and are the medians and IQR of the results from five
experiments performed in triplicate. *p , 0.05 versus
the own control.
FIGURE 7. Effect of ICOS-Fc on b-Pix expression in DCs. iDCs (right)
or mDCs (left) were treated with ICOS-Fc or F119SICOS-Fc (4 mg/ml) for
30 min; then b-Pix and GADPH expression were analyzed by Western
blot. Upper panels show the b-Pix and GADPH expression from the same
gel. Bar graphs show the medians and IQR of the densitometric analysis
from five experiments. *p , 0.05 versus the control.
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only type of APC that can activate naive T cells and initiate the
immune response (36, 43, 54). Key features of this activity are the
abilities of iDCs to migrate to the sites of inflammation in response
to inflammatory chemokines, to endocytose Ags, and to mature to
mDCs moving to the T cell areas of secondary lymphoid organs,
where they present the endocytosed Ags to both MHC-I– and
MHC-II–restricted naive T cells, and initiate the immune response.
Most iDCs reside within the tissues and do not recirculate, but
some of them constitutively traffic to lymph nodes via the afferent
lymph and play a role in the induction of peripheral tolerance (36,
54). Infection and inflammation dramatically increase DC migra-
tion as the result of maturation events that increase DC motility and
responsiveness to lymph tropic chemoattractants (36). In this pro-
cess, mDCs downregulate chemokine receptors, such as CCR1,
CCR2, CCR5, and CXCR1, required for proinflammatory che-
motaxis in the tissues, and upregulate those, such as CCR7, required
for migration to the lymph nodes. Their entry in the afferent lym-
phatics involves ICAM-1 and VCAM-1, and several other adhesion
molecules only partly shared with those involved in the leukocyte
interaction with vascular ECs (36).
In this scenario, our data suggest that B7h triggering may play
a key role in modulating DC function. Its ability to block iDCs
migration would be crucial for arresting these cells in the inflamed
tissues where they can load the Ags in both MHC-II and MHC-I,
favored by the effect of B7h triggering on cross-presentation. Then
its ability to block mDC migration would be crucial to arrest these
cells in the secondary lymphoid tissues where they can activate
both CD4+ and CD8+ T cells and, possibly, support differentiation
of Th17 cells. In this context, the inhibitory effect exerted by B7h
signaling on DC adhesion to ECs might be important to inhibit the
transendothelial migration of these cells and favor their perma-
nence in the tissues.
ICOS-Fc has been used to treat several pathological conditions in
mice with the aim of blocking the ICOS–B7h interaction. However,
this and previous reports suggest that it may also act as an agonist
of B7h signaling, and that these multifaceted effects may account
for the heterogeneous results obtained in different disease models
and using different types of ICOS antagonists. Therefore, before
proposing therapeutic uses of ICOS-Fc, more work is needed to
depict its global effect both in vitro and in vivo.
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Supplementary Table I: Cytokine secretion induced in different lymphocyte population by 
allogeneic DCs treated with different stimuli. 
  
    LPS LPS+ICOS-Fc LPS+ICOS-msFc LPS+
F119SICOS-Fc 
IFN-γ
CD4 1285 [1077-1372]* 1580 [1284-1913] 1222 [1017-1807] 2078 [1404-2966] 
CD8 0 [0-3] 0 [0-34] 0 [0-31] 0 [0-7] 
PBL 1228 [538-2038] 1366 [865-2138] 867 [620-1657] 901 [376-1745] 
IL10 
CD4 57 [38-96] 51 [46-95] 54 [35-59] 49 [34-54] 
CD8  -  -  -  - 
PBL 5 [0-6] 6 [0-10] 7 [0-9] 7 [3-9] 
IL2 CD8 103 [80-137] 86 [85-86] 90 [69-132] 114 [96-132] 
CCL20
CD4 20 [8-36] 21 [13-37] 15 [7-28] 14 [7-21] 
CD8  -  -  -  - 
PBL 2 [0-9] 7 [1-8] 1 [0-8] 1 [0-3] 
    
*Data are expressed as pg/ml and are medians [IQR]. All differences were not significant 
